The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Cyclin-dependent kinase (CDK)4/6 inhibitors are approved for the treatment of breast cancer, and they have more recently been used in patients with well ...

Abnormal cell proliferation is a major hallmark of cancer. Several proteins are involved in the cell cycle, and most of these regulate the positive or negative control of cyclin-dependent kinases.

Proxygen GmbH has disclosed molecular glue degraders comprising a cullin-ring E3 ligase (CRL) binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers. They are ...

Proxygen GmbH has divulged molecular glue degraders comprising a cullin-ring E3 ligase (CRL)-binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers reported to be ...

Zentalis Pharmaceuticals progresses with azenosertib in the DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, aiming for FDA approval by 2026. Part 2a of the trial will determine ...